Billing Codes — Australian Health Schedule Tracker

Showing 5151–5200 of 6045 Pg 104/121

	Item No.	Description	Category	Schedule Fee	100% Benefit	Status
	73065	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies (Item is subject to rule 13) Group P6	Category 6 — Pathology	$90.35	—	≠ CHANGED
Item Number 73065 Schedule Fee $90.35 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.05.2009 Gov. Change Flags Fee ≠ Full Description Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies (Item is subject to rule 13) Sign in to watch this code → Get an email alert when this item changes
	73066	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if a recognized pathologist: (a) performs the aspiration; or (b) attends the aspiration and performs cytological examination during the attendance Group P6	Category 6 — Pathology	$232.65	—	≠ CHANGED
Item Number 73066 Schedule Fee $232.65 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.07.2011 Gov. Change Flags Fee ≠ Full Description Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if a recognized pathologist: (a) performs the aspiration; or (b) attends the aspiration and performs cytological examination during the attendance Sign in to watch this code → Get an email alert when this item changes
	73067	Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy Group P6	Category 6 — Pathology	$135.70	—	≠ CHANGED
Item Number 73067 Schedule Fee $135.70 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.07.2011 Gov. Change Flags Fee ≠ Full Description Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy Sign in to watch this code → Get an email alert when this item changes
	73070	73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer: (a) performed on a liquid based cervical specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, once only in a 57 month period Group P6	Category 6 — Pathology	$36.80	—	≠ CHANGED
Item Number 73070 Schedule Fee $36.80 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description 73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer: (a) performed on a liquid based cervical specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, once only in a 57 month period Sign in to watch this code → Get an email alert when this item changes
	73071	A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer, if performed: (a) on a self‑collected vaginal specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, applicable once in 57 months Group P6	Category 6 — Pathology	$36.80	—	≠ CHANGED
Item Number 73071 Schedule Fee $36.80 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer, if performed: (a) on a self‑collected vaginal specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, applicable once in 57 months Sign in to watch this code → Get an email alert when this item changes
	73072	A test, including partial genotyping, for oncogenic human papillomavirus: (a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre‑cancer or cancer; or (b) for the follow‑up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre‑cancer or cancer; or (c) for the investigation of a patient with symptoms suggestive of cervical cancer; or (d) for the follow‑up management of a patient after treatment of high grade squamous intraepithelial lesions or adenocarcinoma in situ of the cervix; or (e) for the follow‑up management of a patient with glandular abnormalities; or (f) for the follow‑up management of a patient exposed to diethylstilboestrol in utero; or (g) for a patient previously treated for a genital tract malignancy when performed as a co-test for both human papillomavirus (HPV) and liquid-based cytology (LBC). Group P6	Category 6 — Pathology	$36.80	—	≠ CHANGED
Item Number 73072 Schedule Fee $36.80 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description A test, including partial genotyping, for oncogenic human papillomavirus: (a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre‑cancer or cancer; or (b) for the follow‑up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre‑cancer or cancer; or (c) for the investigation of a patient with symptoms suggestive of cervical cancer; or (d) for the follow‑up management of a patient after treatment of high grade squamous intraepithelial lesions or adenocarcinoma in situ of the cervix; or (e) for the follow‑up management of a patient with glandular abnormalities; or (f) for the follow‑up management of a patient exposed to diethylstilboestrol in utero; or (g) for a patient previously treated for a genital tract malignancy when performed as a co-test for both human papillomavirus (HPV) and liquid-based cytology (LBC). Sign in to watch this code → Get an email alert when this item changes
	73074	A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy. Group P6	Category 6 — Pathology	$36.80	—	≠ CHANGED
Item Number 73074 Schedule Fee $36.80 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy. Sign in to watch this code → Get an email alert when this item changes
	73075	A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory Group P6	Category 6 — Pathology	$36.80	—	≠ CHANGED
Item Number 73075 Schedule Fee $36.80 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory Sign in to watch this code → Get an email alert when this item changes
	73076	Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma Group P6	Category 6 — Pathology	$48.30	—	≠ CHANGED
Item Number 73076 Schedule Fee $48.30 Category Category 6 — Pathology Group / Subheading Group P6 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.12.2017 Gov. Change Flags Fee ≠ Full Description Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma Sign in to watch this code → Get an email alert when this item changes
	73287	The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests Group P7	Category 6 — Pathology	$394.55	—
Item Number 73287 Schedule Fee $394.55 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.07.1993 Gov. Change Flags No changes flagged Full Description The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73289	The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests Group P7	Category 6 — Pathology	$358.95	—
Item Number 73289 Schedule Fee $358.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.07.1993 Gov. Change Flags No changes flagged Full Description The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73290	The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests. Group P7	Category 6 — Pathology	$394.55	—
Item Number 73290 Schedule Fee $394.55 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2010 Gov. Change Flags No changes flagged Full Description The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73291	Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests. Group P7	Category 6 — Pathology	$230.95	—
Item Number 73291 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2010 Gov. Change Flags No changes flagged Full Description Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73292	Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests. Group P7	Category 6 — Pathology	$589.90	—
Item Number 73292 Schedule Fee $589.90 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2010 Gov. Change Flags No changes flagged Full Description Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73293	Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests. Group P7	Category 6 — Pathology	$230.95	—
Item Number 73293 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2010 Gov. Change Flags No changes flagged Full Description Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73294	Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests. Group P7	Category 6 — Pathology	$230.95	—
Item Number 73294 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2010 Gov. Change Flags No changes flagged Full Description Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73295	Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73295 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.02.2017 Item from: 01.02.2017 Gov. Change Flags No changes flagged Full Description Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73296	Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73296 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2017 Item from: 01.11.2017 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis Sign in to watch this code → Get an email alert when this item changes
	73297	Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant Group P7	Category 6 — Pathology	$400.00	—
Item Number 73297 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2017 Item from: 01.11.2017 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant Sign in to watch this code → Get an email alert when this item changes
	73298	Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome. Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73298 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2019 Item from: 01.05.2019 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome. Sign in to watch this code → Get an email alert when this item changes
	73299	Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician. Group P7	Category 6 — Pathology	$400.00	—
Item Number 73299 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.05.2019 Item from: 01.05.2019 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician. Sign in to watch this code → Get an email alert when this item changes
	73300	Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests Group P7	Category 6 — Pathology	$101.30	—
Item Number 73300 Schedule Fee $101.30 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2003 Gov. Change Flags No changes flagged Full Description Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73301	A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73301 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.08.2020 Item from: 01.08.2020 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73302	Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis Group P7	Category 6 — Pathology	$400.00	—
Item Number 73302 Schedule Fee $400.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.08.2020 Item from: 01.08.2020 Gov. Change Flags No changes flagged Full Description Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73303	A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis Group P7	Category 6 — Pathology	$1000.00	—
Item Number 73303 Schedule Fee $1000.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.04.2022 Item from: 01.04.2022 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73304	Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime Group P7	Category 6 — Pathology	$1000.00	—
Item Number 73304 Schedule Fee $1000.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.04.2022 Item from: 01.04.2022 Gov. Change Flags No changes flagged Full Description Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73305	Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive Group P7	Category 6 — Pathology	$202.65	—
Item Number 73305 Schedule Fee $202.65 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2003 Gov. Change Flags No changes flagged Full Description Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive Sign in to watch this code → Get an email alert when this item changes
	73306	Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient Group P7	Category 6 — Pathology	$1200.00	—
Item Number 73306 Schedule Fee $1200.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2023 Item from: 01.11.2023 Gov. Change Flags No changes flagged Full Description Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient Sign in to watch this code → Get an email alert when this item changes
	73307	A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis Group P7	Category 6 — Pathology	$3000.00	—
Item Number 73307 Schedule Fee $3000.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.01.2024 Item from: 01.01.2024 Gov. Change Flags No changes flagged Full Description A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73308	Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests Group P7	Category 6 — Pathology	$36.45	—
Item Number 73308 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2006 Gov. Change Flags No changes flagged Full Description Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73309	A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Group P7	Category 6 — Pathology	$36.45	—
Item Number 73309 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2007 Gov. Change Flags No changes flagged Full Description A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73310	Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist Group P7	Category 6 — Pathology	$1550.00	—
Item Number 73310 Schedule Fee $1550.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.11.2023 Item from: 01.11.2023 Gov. Change Flags No changes flagged Full Description Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist Sign in to watch this code → Get an email alert when this item changes
	73311	Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests Group P7	Category 6 — Pathology	$36.45	—
Item Number 73311 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2006 Gov. Change Flags No changes flagged Full Description Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73312	A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Group P7	Category 6 — Pathology	$36.45	—
Item Number 73312 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2007 Gov. Change Flags No changes flagged Full Description A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73313	Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse Group P7	Category 6 — Pathology	$3000.00	—
Item Number 73313 Schedule Fee $3000.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2024 Item from: 01.07.2024 Gov. Change Flags No changes flagged Full Description Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse Sign in to watch this code → Get an email alert when this item changes
	73314	Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia; Group P7	Category 6 — Pathology	$230.95	—
Item Number 73314 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2006 Gov. Change Flags No changes flagged Full Description Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia; Sign in to watch this code → Get an email alert when this item changes
	73315	A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Group P7	Category 6 — Pathology	$230.95	—
Item Number 73315 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2007 Gov. Change Flags No changes flagged Full Description A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73316	Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies Group P7	Category 6 — Pathology	$780.00	—
Item Number 73316 Schedule Fee $780.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2024 Item from: 01.07.2024 Gov. Change Flags No changes flagged Full Description Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies Sign in to watch this code → Get an email alert when this item changes
	73317	Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20) Group P7	Category 6 — Pathology	$36.45	—
Item Number 73317 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2006 Gov. Change Flags No changes flagged Full Description Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20) Sign in to watch this code → Get an email alert when this item changes
	73318	A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20) Group P7	Category 6 — Pathology	$36.45	—
Item Number 73318 Schedule Fee $36.45 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2007 Gov. Change Flags No changes flagged Full Description A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20) Sign in to watch this code → Get an email alert when this item changes
	73319	Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime Group P7	Category 6 — Pathology	$340.00	—
Item Number 73319 Schedule Fee $340.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: D Fee: N Benefit: C Effective Dates Fee from: 01.07.2025 Item from: 01.07.2025 Gov. Change Flags No changes flagged Full Description Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73320	Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27) Group P7	Category 6 — Pathology	$40.55	—
Item Number 73320 Schedule Fee $40.55 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2006 Gov. Change Flags No changes flagged Full Description Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27) Sign in to watch this code → Get an email alert when this item changes
	73321	A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27) Group P7	Category 6 — Pathology	$40.55	—
Item Number 73321 Schedule Fee $40.55 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2007 Gov. Change Flags No changes flagged Full Description A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27) Sign in to watch this code → Get an email alert when this item changes
	73322	Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime Group P7	Category 6 — Pathology	$186.75	—	≠ CHANGED
Item Number 73322 Schedule Fee $186.75 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2026 Item from: 01.11.2025 Gov. Change Flags Fee ≠ Full Description Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73323	Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed. Group P7	Category 6 — Pathology	$40.55	—
Item Number 73323 Schedule Fee $40.55 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.11.2007 Gov. Change Flags No changes flagged Full Description Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed. Sign in to watch this code → Get an email alert when this item changes
	73324	A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18) Group P7	Category 6 — Pathology	$40.95	—
Item Number 73324 Schedule Fee $40.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.11.2008 Gov. Change Flags No changes flagged Full Description A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18) Sign in to watch this code → Get an email alert when this item changes
	73325	Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm Group P7	Category 6 — Pathology	$90.00	—
Item Number 73325 Schedule Fee $90.00 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.07.2022 Item from: 01.07.2011 Gov. Change Flags No changes flagged Full Description Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm Sign in to watch this code → Get an email alert when this item changes
	73326	Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests Group P7	Category 6 — Pathology	$230.95	—
Item Number 73326 Schedule Fee $230.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.07.2011 Gov. Change Flags No changes flagged Full Description Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73327	Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests Group P7	Category 6 — Pathology	$51.95	—
Item Number 73327 Schedule Fee $51.95 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.07.2011 Gov. Change Flags No changes flagged Full Description Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73332	An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled. Group P7	Category 6 — Pathology	$315.40	—
Item Number 73332 Schedule Fee $315.40 Category Category 6 — Pathology Group / Subheading Group P7 Type Codes Item: S Fee: N Benefit: C Effective Dates Fee from: 01.01.2013 Item from: 01.05.2012 Gov. Change Flags No changes flagged Full Description An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled. Sign in to watch this code → Get an email alert when this item changes

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies (Item is subject to rule 13)

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if a recognized pathologist: (a) performs the aspiration; or (b) attends the aspiration and performs cytological examination during the attendance

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer: (a) performed on a liquid based cervical specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, once only in a 57 month period

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer, if performed: (a) on a self‑collected vaginal specimen; and (b) for an asymptomatic patient who is at least 24 years and 9 months of age For any particular patient, applicable once in 57 months

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus: (a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre‑cancer or cancer; or (b) for the follow‑up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre‑cancer or cancer; or (c) for the investigation of a patient with symptoms suggestive of cervical cancer; or (d) for the follow‑up management of a patient after treatment of high grade squamous intraepithelial lesions or adenocarcinoma in situ of the cervix; or (e) for the follow‑up management of a patient with glandular abnormalities; or (f) for the follow‑up management of a patient exposed to diethylstilboestrol in utero; or (g) for a patient previously treated for a genital tract malignancy when performed as a co-test for both human papillomavirus (HPV) and liquid-based cytology (LBC).

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy.

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests.

Fee From

01.02.2017

Category

Category 6 — Pathology

Description

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime

Fee From

01.11.2017

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis

Fee From

01.11.2017

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant

Fee From

01.05.2019

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome.

Fee From

01.05.2019

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests

Fee From

01.08.2020

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis

Fee From

01.08.2020

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis

Fee From

01.04.2022

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis

Fee From

01.04.2022

Category

Category 6 — Pathology

Description

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive

Fee From

01.11.2023

Category

Category 6 — Pathology

Description

Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient

Fee From

01.01.2024

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

Fee From

01.11.2023

Category

Category 6 — Pathology

Description

Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

Fee From

01.07.2024

Category

Category 6 — Pathology

Description

Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia;

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

Fee From

01.07.2024

Category

Category 6 — Pathology

Description

Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20)

Fee From

01.07.2025

Category

Category 6 — Pathology

Description

Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27)

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27)

Fee From

01.07.2026

Category

Category 6 — Pathology

Description

Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18)

Fee From

01.07.2022

Category

Category 6 — Pathology

Description

Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests

Fee From

01.01.2013

Category

Category 6 — Pathology

Description

An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.

← Prev 102 103 104 105 106 Next →

50 items per page · tap/click any row to expand

MBS Item Tracker